Almirall predicts positive 2021 development of psoriasis product

Dermatology company Almirall retreated in 2020 due to generic competition and Covid-19-related challenges, but the firm expects progress in 2021, aided by two of the firm's newest products.
Photo: Mikkel Aabenhus Hemmingsen / MedWatch
Photo: Mikkel Aabenhus Hemmingsen / MedWatch
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

In early 2020, already, Almirall warned this wouldn't be the best year. Competition from US generic products would have a severe impact, and the firm was facing a series of investments.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading